Resistance to Integrase Inhibitors
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Integrase (IN) is a clinically validated target for the treatment of human immunodeficiency virus infections and raltegravir exhibits remarkable clinical activity. The next most advanced IN inhibitor is elvitegravir. However, mutant viruses lead to treatment failure and mutations within the IN coding sequence appear to confer cross-resistance. The characterization of those mutations is critical for the development of second generation IN inhibitors to overcome resistance. This review focuses on IN resistance based on structural and biochemical data, and on the role of the IN flexible loop i.e., between residues G140-G149 in drug action and resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131 · cited 7×
“L-870,810 (Merck & Co.) and S-1360 (Shionogi & Co. Ltd. and GlaxoSmithKline) were the first DKA-like IN inhibitors to reach clinical trials.”
BackgroundMethodInfluentialDyda, F., Hickman, A. B., Jenkins, T. M., Engelman, A., Craigie, R., & Davies, D. R. (1994) · Science · doi:10.1126/science.7801124 · Cited by 810 · cited 1×
“Even if the structure of the whole protein has not been resolved yet, several crystals of the isolated domains [17-19] or combinations of two domains of IN [20,21] have been obtained.”
BackgroundRetroviral intasome assembly and inhibition of DNA strand transfer
Hare, S., Gupta, S. S., Valkov, E., Engelman, A., & Cherepanov, P. (2010) · Nature · doi:10.1038/nature08784 · Cited by 678 · cited 5×
“Also, the flexible loop appears involved in RAL and EVG binding, highlighting a crucial role of the flexible loop in both IN activity and drug resistance [32].”
BackgroundInfluentialStructural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75
Cherepanov, P., Ambrosio, A. L. B., Rahman, S., Ellenberger, T., & Engelman, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506924102 · Cited by 408
Chen, J. C.-H., Krucinski, J., Miercke, L. J. W., Finer-Moore, J. S., Tang, A. H., Leavitt, A. D., & Stroud, R. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150220297 · Cited by 404
Grobler, J. A., Stillmock, K., Hu, B., Witmer, M., Felock, P., Espeseth, A. S., Wolfe, A., Egbertson, M., Bourgeois, M., Melamed, J., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092056199 · Cited by 399 · cited 1×
“As for DKA, RAL’s inhibition mechanism is specific for the ST step of integration and proposed to involve chelation of one or two metals within the IN active site after processing of the bound viral DNA ends [45,46].”
BackgroundDeJesus, E., Berger, D., Markowitz, M., Cohen, C., Hawkins, T., Ruane, P., Elion, R., Farthing, C., Zhong, L., Cheng, A. K., et al. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000233308.82860.2f · Cited by 270 · cited 1×
“EVG is metabolized in vivo by cytochrome P450 and glucuronidation [48], and co-administration with ritonavir (PR inhibitor) increases EVG systemic concentrations by about 20-fold, consistent with a possible once daily use of the drug [75].”
BackgroundThe lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication
Engelman, A., & Cherepanov, P. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000046 · Cited by 231 · cited 4×
“The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication.”
BackgroundInfluentialRetroviral integrase superfamily: the structural perspective
Nowotny, M. (2009) · The EMBO Reports · doi:10.1038/embor.2008.256 · Cited by 183 · cited 1×
“The central catalytic core domain (CCD) contains amino acids 50-212 and harbors the catalytic DDE motif (D64D116E152) well conserved among the retroviral integrase superfamily [16].”
BackgroundFunctional and structural characterization of the integrase from the prototype foamy virus
Valkov, E., Gupta, S. S., Hare, S., Helander, A., Roversi, P., McClure, M., & Cherepanov, P. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn938 · Cited by 130
Cited by
The structural biology of HIV-1: mechanistic and therapeutic insights
Engelman, A., & Cherepanov, P. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2747 · Cited by 424
Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance
Hare, S., Vos, A. M., Clayton, R. F., Thuring, J. W., Cummings, M. D., & Cherepanov, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010246107 · Cited by 305
Hare, S., Smith, S. J., Métifiot, M., Jaxa-Chamiec, A., Pommier, Y., Hughes, S. H., & Cherepanov, P. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.073189 · Cited by 264
Self-citationInterfacial inhibitors: targeting macromolecular complexes
Pommier, Y., & Marchand, C. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3404 · Cited by 259
Self-citationHightower, K. E., Wang, R., DeAnda, F., Johns, B. A., Weaver, K., Shen, Y., Tomberlin, G. H., Carter, H. L., Broderick, T., Sigethy, S., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00157-11 · Cited by 226
Metadata
- Authors
- Métifiot, M., Marchand, C., Maddali, K., & Pommier, Y.
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2010-06-25
- Volume
- 2
- Issue
- 7
- Pages
- 1347-1366
- ISSN
- 1999-4915 (ISSN-L)
- OpenAlex
- W2150226114
- Cited by
- 99
- References
- 10
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resistance to Integrase Inhibitors. https://app.cochat.ai/papers/10.3390/v2071347
- The paper
- Métifiot, M., Marchand, C., Maddali, K., & Pommier, Y. (2010). Resistance to Integrase Inhibitors. Viruses. https://doi.org/10.3390/v2071347
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.